127 related articles for article (PubMed ID: 4083263)
1. Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.
Chiuten DF; Miller A; Valdivieso M; Loo TL; Bedikian A; Bodey GP; Benvenuto JA; Freireich EJ
Am J Clin Oncol; 1985 Aug; 8(4):332-5. PubMed ID: 4083263
[TBL] [Abstract][Full Text] [Related]
2. Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination.
Chiuten DF; Valdivieso M; Bedikian A; Bodey GP; Freireich EJ
Cancer Treat Rep; 1985 Jun; 69(6):611-3. PubMed ID: 4016768
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
Ardalan B; Singh G; Silberman H
J Clin Oncol; 1988 Jun; 6(6):1053-8. PubMed ID: 3373260
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
Ardalan B; Ucar A; Reddy R; Livingstone AS; Markoe A; Schwade J; Richman SP; Donofrio K
Cancer; 1994 Oct; 74(7):1869-73. PubMed ID: 8082092
[TBL] [Abstract][Full Text] [Related]
6. Phase I evaluation of a biochemically designed combination: PALA, thymidine, and 5-FU.
Casper ES; Michaelson RA; Kemeny N; Martin DS; Young CW
Cancer Treat Rep; 1984 Mar; 68(3):539-41. PubMed ID: 6704982
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study.
Martino RL; Fleming TR; Morrell LM; Ardalan B; Richman SP; Macdonald JS
Invest New Drugs; 1996; 14(4):419-21. PubMed ID: 9157080
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial of sequential N-phosphonacetyl-L-aspartate, thymidine, and 5-fluorouracil in advanced colorectal carcinoma.
O'Connell MJ; Moertel CG; Rubin J; Hahn RG; Kvols LK; Schutt AJ
J Clin Oncol; 1984 Oct; 2(10):1133-8. PubMed ID: 6491697
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of combination therapy with PALA and 5-FU.
Meshad MW; Ervin TJ; Kufe D; Johnson RK; Blum RH; Frei E
Cancer Treat Rep; 1981; 65(3-4):331-4. PubMed ID: 6263472
[TBL] [Abstract][Full Text] [Related]
10. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.
Van Echo DA; Diggs CH; Scoltock M; Wiernik PH
Cancer Treat Rep; 1980; 64(2-3):339-42. PubMed ID: 7407767
[TBL] [Abstract][Full Text] [Related]
11. Phase I evaluation and pharmacokinetic study of weekly iv thymidine and 5-FU in patients with advanced colorectal carcinoma.
Lynch G; Kemeny N; Chun H; Martin D; Young C
Cancer Treat Rep; 1985 Feb; 69(2):179-84. PubMed ID: 3971391
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
O'Dwyer PJ; Hudes GR; Colofiore J; Walczak J; Hoffman J; LaCreta FP; Comis RL; Martin DS; Ozols RF
J Natl Cancer Inst; 1991 Sep; 83(17):1235-40. PubMed ID: 1714507
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.
Weiss GR; Ervin TJ; Meshad MW; Schade D; Branfman AR; Bruni RJ; Chadwick M; Kufe DW
Cancer Chemother Pharmacol; 1982; 8(3):301-4. PubMed ID: 7127661
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer.
Mann GB; Hortobagyi GN; Buzdar AU; Yap HY; Valdivieso M
Cancer; 1985 Sep; 56(6):1320-4. PubMed ID: 4027872
[TBL] [Abstract][Full Text] [Related]
15. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Ardalan B; Sridhar KS; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Fodor M; Livingstone A
Cancer; 1991 Sep; 68(6):1242-6. PubMed ID: 1873776
[TBL] [Abstract][Full Text] [Related]
16. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
Erlichman C; Donehower RC; Speyer JL; Klecker R; Chabner BA
J Natl Cancer Inst; 1982 Feb; 68(2):227-31. PubMed ID: 6950156
[TBL] [Abstract][Full Text] [Related]
17. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
Buroker TR; Moertel CG; Fleming TR; Everson LK; Cullinan SA; Krook JE; Mailliard JA; Marschke RF; Klaassen DJ; Laurie JA
J Clin Oncol; 1985 Dec; 3(12):1624-31. PubMed ID: 2933492
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
O'Dwyer PJ; Paul AR; Walczak J; Weiner LM; Litwin S; Comis RL
J Clin Oncol; 1990 Sep; 8(9):1497-503. PubMed ID: 2391557
[TBL] [Abstract][Full Text] [Related]
19. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
Casper ES; Gralla RJ; Kelsen DP; Houghton A; Golbey RB; Young CW
Cancer Treat Rep; 1980; 64(4-5):705-7. PubMed ID: 6448688
[No Abstract] [Full Text] [Related]
20. A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer.
Windschitl HE; O'Connell MJ; Wieand HS; Krook JE; Rubin J; Moertel CG; Kugler JW; Pfeifle DM; Goldberg RM; Laurie JA
Cancer; 1990 Sep; 66(5):853-6. PubMed ID: 2201430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
